SCHEMBL2086850

SCHEMBL2086850

c1ccc([N]c2ccc3ccc4cccc5ccc2c3c45)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.47
ERBB2 P04626 1/20 0.47
FYN P06241 1/20 0.47
MAOA P21397 1/20 0.47
ACHE P22303 1/20 0.47
AHR P35869 1/20 0.47
ALDH1A1 P00352 7/20 0.46
HPGD P15428 5/20 0.46
HSD17B10 Q99714 5/20 0.46
THRB P10828 2/20 0.46
TSHR P16473 3/20 0.45
CYP3A4 P08684 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP1A1 P04798 1/20 0.44
CYP1B1 Q16678 1/20 0.44
KMT2A Q03164 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 2/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837799 0.85 ALDH1A1 (0.55) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL2290967 0.78 HPRT1 (0.54) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL69928 0.77 CYP1A2 (0.50) CYP1A2MAOAALDH1A1HPGDHSD17B10
SCHEMBL7751770 0.77 CYP1A2 (0.50) CYP1A2MAOAALDH1A1HPGDHSD17B10
SCHEMBL28872577 0.72 ALDH1A1 (0.50) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL28272111 0.72 ALDH1A1 (0.50) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL3341373 0.72 ALDH1A1 (0.50) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL348429 0.72 SIGMAR1 (0.41) CYP1A2ERBB2FYNMAOAACHE
Pyrene SCHEMBL27863015 0.71 ALDH1A1 (0.67) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL9057553 0.71 ALDH1A1 (0.47) CYP1A2ERBB2FYNMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9028976-B2 Organic EL device FUTABA CORPORATION (JP) 2015-05-12 US claimed
US-9028976-B2 Organic EL device FUTABA CORPORATION (JP) 2015-05-12 US disclosed
US-20110295017-A1 Organic EL Device TDK CORPORATION (JP) 2011-12-01 US disclosed
US-20110049482-A1 Novel aromatic compound and organic electroluminescent element containing the same IDEMITSU KOSAN CO., LTD. (JP) 2011-03-03 US disclosed
US-7790892-B2 Aromatic compound and organic electroluminescent element containing the same IDEMITSU KOSAN CO., LTD. (JP) 2010-09-07 US disclosed
US-20050214565-A1 Novel aromatic compound and organic electroluminescent element containing the same IDEMITSU KOSAN CO., LTD. (JP) 2005-09-29 US disclosed
EP-1496041-A1 NOVEL AROMATIC COMPOUND AND ORGANIC ELECTROLUMINESCNET ELEMENT CONTAINING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2005-01-12 EP disclosed
EP-1079668-A2 El display apparatus TDK Corporation (JP) 2001-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295017-A1 Organic EL Device LEF1, ELP1, MLLT1 CYP1A2 668/4885ERBB2 1662/4885FYN 2794/4885
US-20110049482-A1 Novel aromatic compound and organic electroluminescent element containing the same TYR, EML4, TCF7L2 CYP1A2 644/4885ERBB2 2670/4885FYN 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.